How much cash does Spyre Therapeutics, Inc. generate?

Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.

Where does Spyre Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Spyre Therapeutics, Inc. SYRE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$155.2M+25.4%	-$208.02M+38.6%	-$338.79M-304%	-$83.82M-27.4%
Stock-based compensation	$37.61M-16.1%	$44.85M+74.7%	$25.68M+261%	$7.11M-11.5%
Net cash from operating activities	-$169.25M-7.5%	-$157.41M-57.6%	-$99.91M-24.7%	-$80.14M-43.6%
Net cash from investing activities	-$143.48M—	——	-$108.39M-290%	$57.01M—
Net cash from financing activities	$309.03M-24.8%	$410.91M+10.0%	$373.61M—	——
Net increase (decrease) in cash	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Spyre Therapeutics, Inc. generate?: Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
Where does Spyre Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.